Source: Chelsea Laskowski, CBC News, May 1, 2019
Up until last year, there were no Health Canada-approved drugs for the most aggressive form of MS
Saskatchewan is the third province in Canada to fully fund a new multiple sclerosis drug under the provincial drug plan, according to the Saskatchewan branch of the Multiple Sclerosis Society of Canada (MSSC).
The drug is called Ocrevus. It’s typically delivered by IV every six months into patients with two of the four types of multiple sclerosis (MS): primary progressive MS and relapsing remitting MS.
